Research programme: spinal cord injury cell therapy - Noscira

Drug Profile

Research programme: spinal cord injury cell therapy - Noscira

Alternative Names: GOE; OEG

Latest Information Update: 07 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Noscira
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 18 Dec 2012 Noscira is in liquidation
  • 18 Dec 2012 Discontinued - Preclinical for Spinal cord injuries in Spain (Parenteral)
  • 15 Mar 2010 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top